A quartet of European biotech units wins $5.2 million to advance research in artificial livers to treat metabolic diseases or for whole-organ transplants.
E.U. biotech quartet wins $5.2M for artificial liver research
A group of European biotechnology developers won $5.2 million (€4.2 million) to advance their collaborative work on artificial liver tissue.
The consortium is working on a "standardized, reproducible bioartificial liver organoid" using a healthy human liver as the template.
The "Re-Liver" program is a collaboration between Medicyte, The Electrospinning Company, and the Universities of Manchester, U.K., and Pisa, Italy.